Our ancestors expected blood to clot when it left the body or when it stayed in the blood vessels after death. They were, therefore, puzzled by the incoagulability of menstrual blood and by Hunter's finding in 1794 that in "animals killed by lightning or electricity . . . or who are run very hard and killed in such a state" the blood also remained incoagulable.I The next century saw the unravelling of these mysteries and the provision of important clues to an entirely new approach to the management of thrombosis. 2 If shed clotted blood is incubated its fibrin coagulum slowly dissolves and the addition of the powerful procoagulant, thrombin, will not produce any further clotting.3 By the beginning ofthe twentieth century it had been shown that not only was the blood from victims of violent death incoagulable and free of fibrin but that it would also render normal blood incoagulable by digesting its fibrin. This "fibrinolytic activity" was shown to reside in the globulin fraction of the plasma. During this century we have seen the clarification of the lytic pathway by the identification of the inactive ,3 globulin precursor plasminogen, which is capable of being converted to the active serine protease enzyme, plasmin. Plasmin is non-specifically proteolytic and so not only attacks fibrin but also breaks down other proteins, including fibrinogen and members of the clotting cascade. The debates about the part played by "natural fibrinolysis" in the normal economy of the body need not concern us here, but it is still far from clear whether there is a balance between the coagulation and the fibrinolytic pathways which maintains our blood in an appropriate state of fluidity and, if so, whether disturbances of this balance make any contribution to thrombotic disease. Of more immediate relevance is to ask ourselves whether we can harness the clot dissolving properties of the plasminogen-plasmin system in the treatment of thrombi which have already formed and are about to produce infarction.
Harnessing the lytic system
Early attempts to capitalise on the fibrinolytic system were rather basic; in 1936 Judine "put post-mortem fibrinolysis to practical use by designing a corpse blood transfusion service, the donors being those who had died suddenly and whose blood, consequently fluid, required no anticoagulant."' At the same time Tillett and Garner, at the Rockefeller Institute, were reporting that filtrates of haemolytic streptococci could cause rapid liquefaction of human fibrin,4 and by 1945 Christensen and MacLeod had shown that the bacteria were producing an activator of the fibrinolytic system, which they called streptokinase. 5 We now know that this is a single chain protein with a molecular weight of 48 000 daltons, that it does not activate plasminogen directly but complexes with it, and that this complex is then converted into active plasmin. When we come to consider how to get fibrinolytic activity to the place where we want it (the harmful thrombus) and not to the places which we wish to spare (the helpful haemostatic mechanisms) the relevance of this will become apparent. Streptokinase is antigenic so that its administration may cause fever and allergic reactions, but of more importance is that it stimulates antibody production, so that treatment for more than a few days is impracticable. Are we now agreed on the target? When an eminent physicist was asked why the bitter debate between the proponents of the corpuscular and the wave train theories of light transmission had ended he said it was because all the proponents of the corpuscular theory had died. Beliefs often show generation linked swings, and the hard evidence linking myocardial infarction to occlusive thrombosis which had been carefully collected during the 1930s was forgotten by the 1950s such that it was possible to attend conferences on "atherosclerotic heart disease" without hearing thrombosis mentioned. We thought that our Oxford necropsy study had finally re-established the central part played by thrombotic luminal occlusion in the genesis of transmural myocardial infarction,'2 but no sooner was the ink dry on our papers than quaint notions began to emerge as suggested causes of heart attack-thrombus being claimed as a secondary consequence ofnecrotising myocardial disease or of coronary spasm, while other workers claimed that they found no thrombi, whether primary or secondary, in the hearts they examined. Let us hope that the painstaking work of Davies and Thomas has ended this cyclical "now you see it, now you don't" saga by showing that disruption of plaques accompanied by thrombosis provides a well documented basis for both acute myocardial infarction and sudden cardiac death. ' Learning from the past
The only weapons available to attack thrombi in the 1960s were streptokinase and urokinase, and because direct access to the coronary circulation had not become the everyday affair that it is today the lytic activators had to be given by intravenous infusion. The approach to clinical trials was less rigorous at that time, and most studies were too small to allow benefit to be proved or refuted; moreover, they differed widely in their choice of patients, their treatment regimens, their end points, and their pattern of follow up. These disparities have been set out clearly by Yusuf and his colleagues. 4 The only way forward is to mount large scale cooperative studies, and three early steps were taken in this direction. The European Working Party compared intravenous streptokinase with intravenous heparin in 730 patients with acute myocardial infarction,' and the European Collaborative Study randomised 341 patients to either intravenous urokinase plus anticoagulants or to anticoagulants alone. 6 Neither trial produced clear cut results, but the lessons learnt from them about recruitment, analysis, and reporting stood the group in good stead, for its final study of this era set out clearly who had been considered for entry ( The impossibility of combating a mass disease with intracoronary infusions prompted the second development, which was to mount larger collaborative trials of intravenous lytic treatment with streptokinase, urokinase, and recombinant plasminogen activators in such a way that modest but technically feasible benefits could be documented. '8 The battles which will dominate our thinking for the next decade are thus intracoronary versus intravenous treatment, and as the weapons which the two sides will be using are the same the armaments manufacturers will be vying with each other to prove that streptokinase kills more enemy troops at less cost than recombinant plasminogen activators or that acylated streptokinase hits its target more effectively than urokinase or its homing derivative, prourokinase.
Does the route matter?
The units which were able to attack occluded coronary arteries directly were also able to show the immediate efficacy of their lytic treatment by serial coronary angiography, but the early reports were based on tiny numbers and concentrated on patency rates rather than on benefit to patients. This important distinction between process and outcome contains the key to what we must ask of the trials we are now mounting. For example, an early report showed that in nine patients intracoronary streptokinase given some three and a half hours after onset reopened the occluded segments in all of them but that in one patient reocclusion occurred. '9 By 1983 the groups were larger, but there were still problems of selective investigation in that in a typical study coronary arteriograms were performed only in the 24 patients receiving intracoronary streptokinase, showing clearance in 19, whereas the anatomy of the 26 control patients was not described.20 Ventricular function was claimed to be better in the streptokinase group, but once again this was a doctor based end point-a process-whereas what the patient wants to know is whether he will live or die-an outcome. Not all groups agreed that even these process changes were occurring, for another study in 1983 reported that though reperfusion rates were indeed different in patients given intracoronary streptokinase (12 
Later that year the first report of the Western Washington group appeared, in which 250 patients were randomly assigned to intracoronary streptokinase or to conventional coronary care treatment. 22 The mean time to random assignment was four and a half hours, and the reperfusion rate in the intracoronary streptokinase group was 68% compared with 12% in the controls, so we were already seeing a less rosy picture than in the earlier, highly selected reports. The 30 day mortality was five out of 134 patients treated with streptokinase (3 7%) and 13 out of 116 controls (11.2%; p<O0O2), so for the first time the claim was made that outcome as well as process was being influenced. Last year saw the completion of the 12 month follow up of these Western Washington patients23 and the reporting of a larger European study.24 In the former the differences seen at 30 days had dwindled into insignificance at one year (11 deaths out of 134 patients given streptokinase (8 2%) as against 17 out of 116 controls (14-7%); p=0-10). In words that will strike terror into the heart of any trial analyst the authors dismiss this negative result by suggesting that "when a minor imbalance in the ejection fraction and infarct location between the two groups was adjusted by logistic regression, the difference in one year mortality became significant." I am sure others will share my scepticism about such retrospective special pleading.
In the study carried out in the Netherlands, 533 patients admitted within four hours of the onset of symptoms were randomly allocated to conventional coronary care treatment or to intracoronary streptokinase alone in the early stages of the trial but preceded by intravenous streptokinase in the last 117 patients randomised to active treatment. This study thus muddies the waters for comparisons between intracoronary and intravenous regimens, but it did show differences in 28 day mortality (streptokinase 6%; control 12%; p=0 03) and one year mortality (9% v 16%; p0= 01). The differences were greater when the patients in the second phase (who had also received intravenous streptokinase) were considered separately. A price was paid in terms of complications of treatment: 53 of the treated patients bled compared with seven controls and transfusions were needed in 48 patients out of the 269 offered thrombolytic treatment.
In 1983 most people agreed with me that acute intracoronary thombolysis had "about as much relevance to the community problem of coronary disease as does a flag carrying national airline or a Western style medical school to a developing country. The mind boggles at the thought of carrying out coronary arteriography in all patients with suspected infarction who are seen within four hours of onset, and the impact of such a development on demands for finance, medical and nurse staffing, and equipment would be enormous. Moreover, coronary arteriography may kill and is not for the amateur; myocardial salvage units would initially need to be based in existing subregional invasive cardiology They concluded, "favourable relative effects were noted on cardiac function, clinical evaluations and hospital course after intravenous streptokinase in early survivors of myocardial infarction and use of an intravenous drug has the advantage of earlier and easier application. Additional studies will be required to address effects on mortality."
Ancient versus modern
Intravenous versus intracoronary streptokinase is largely a battle within the profession relating to the provision and the value of a high technology approach available to the few or a low technology approach which could be made very widely available. Not so the battle which is now being joined between the old (streptokinase and urokinase) and the new (recombinant tissue plasminogen activator, acylated streptokinase, and prourokinase), which will be a multimillion pound struggle between the titans of the pharmaceutical industry for a share of a massive potential world market. The first shots were fired in 1984 by a joint Leuven/St Louis group which went on from studies in animals to show that intravenous or intracoronary recombinant tissue plasminogen activator could induce thrombolysis in six out of seven patients with evolving myocardial infarction "without concomitant induction of a systemic lytic state."30 The bigger guns were fired by the larger United States/Belgian group later that year in its report of 45 patients randomised to receive intravenous recombinant tissue plasminogen activator or placebo plus five additional patients treated with recombinant tissue plasminogen activator.3' Of the patients given recombinant tissue plasminogen activator, three quarters showed recanalisation compared with only one of the 14 patients treated with placebo. Furthermore, the remaining 13 members of this placebo group with persistently occluded vessels were then given intracoronary recombinant tissue plasminogen activator and nine of them achieved patency within 45 minutes. Once again there was no evidence of systemic lysis.
Meantime a European based group was adding to the barrage supporting the advance of recombinant tissue plasminogen activator by randomising 64 patients within six hours of onset to receive intravenous recombinant tissue plasminogen activator over 90 minutes and 65 patients to receive 15 million U of intravenous streptokinase over 60 minutes.32 The patency rates of the "infarct related" coronary arteries on "assessable coronary angiograms" were 70% and 55%, but shrewd observers will note that the duration of the two treatments was different, and that value judgments about the vessel to be assessed and the quality of the angiograms have crept in. Nevertheless, the old hat streptokinase still cleaned out over half the occluded vessels, so we now need to ask, How much will it cost to procure the extra 15% patency rate? Mortality was identical in the two groups, and, though the bleeding complications before discharge from hospital were 21 in the recombinant tissue plasminogen activator group and 39 with streptokinase, the similar transfusion requirements (four patients versus five) showed that there was little to choose between the regimens in terms of major bleeding.
As Comparative efficacy-There has been detailed preliminary study of the most appropriate thrombolytic regimen for intravenous recombinant tissue plasminogen activator, whereas the streptokinase regimens with which they have been compared have not been similarly optimised and have been derived from current practice. Moreover, recombinant tissue plasminogen activator was given for 180 minutes in the thrombosis in myocardial infarction study and 90 minutes in the European study, whereas streptokinase was given for only 60 minutes in each.
Comparative safety-Sherry is not convinced that recombinant tissue plasminogen activator is a "magic bullet" hitting only its thrombotic target and sparing the haemostatic mechanism. He points to the similar major bleeding rates which I have set out above and suggests that when heparin is used, as it was in all the studies analysed, to prevent rethrombosis on the original unstable plaques, then the dose and the nature of the activator have less importance.
Antigenicity-The original tissue plasminogen activator was derived from a human melanoma cell line, but mass production has now switched to using mammalian cells encoded with the tissue plasminogen activator information. Allergic reactions, either during treatment or on retreatment after an interval, will need to be recorded and reported in the studies on recombinant tissue plasminogen activator.
Cost-Urokinase has long been known to be nonantigenic, to be more specific for fibrin, and to have a shorter half life than streptokinase, but because of its cost it has not replaced streptokinase as the most widely used activator. What the cost of saving a life with recombinant tissue plasminogen activator is now or what it will be in 10 years' time cannot readily be answered, but it seems likely to be very substantial. We must therefore ensure that the social and economic costs and benefits of saving that life are going to be fully evaluated.
Verstraete, who like me has lived through the ages of enthusiasm, disillusionment, and now reawakening for anticoagulants and fibrinolysis,2 36 reinforces many of these points and a paraphrase of his comments provides an appropriate "state of the art" summary"':
Coronary thrombi can be safely lysed by both intracoronary and intravenous agents; widespread application of intracoronary thrombolysis is not practicable; high dose, short duration intravenous treatment produces acceptable reperfusion rates without major bleeding problems and can be applied in ordinary district hospitals; targeted activators such as recombinant tissue plasminogen activator or acylated streptokinase probably do have advantages, but a full comparative appraisal of costs and benefits must await the results of trials; and early coronary reperfusion may improve myocardial infarction so could resolve my patient's question, "Will I live longer and if so will I be less disabled?"
All the trials reported above have dealt mainly with process and not with outcome, so we must await the detailed analysis of the recently published GISSI study, which randomised 11 712 patients with acute myocardial infarction to receive either intravenous streptokinase or routine coronary care, the 21 day mortality being 10-7% in the treated group and 13% in the controls. 38 Other acronymic trials are already nearing completion (the German ISAM with some 2000 patients similarly randomised), are getting under way (TIMI 2 with recombinant tissue plasminogen activator, and isis 2 with streptokinase), or are in their final planning stages (ASSET-a joint study of recombinant tissue plasminogen activator versus placebo between Britain and Norway).
Summary
As Verstraete says,37 "To offer the benefit of an effective thrombolytic treatment to a greater proportion of patients as soon as possible after their myocardial infarction, short and simple therapeutic schemes must be developed. The logistics are in favour of an intravenous route for the safest of the thrombolytic drugs. The protective effect of timely reperfusion ... on short and long term morbidity and mortality will hopefully be established in ongoing trials with sufficient statistical power." We are nowhere near this point at present, but I have no doubt that, just as the 1950s was the anticoagulant decade, the 1960s the decade of enthusiasm for
